09/13/2021
What are used to treat ?
✓ Many early evidences, anecdotal reports, and small clinical trials suggested the efficacy of phytocannabinoids in epilepsy.
∆ CBD: CBD is the most commonly analyzed anticonvulsant phytocannabinoid with sufficient data in many acute animal models but limited data in chronic models. Literature has reported nearly more than 65 molecular targets of . The exact mechanism of action of CBD as the anti-epileptic drug is still unknown, but literature documented the effect of CBD on the equilibrative nucleoside transporter(ENT), the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the α3 and α1 glycine receptors. Numerous studies also document the neuroprotective and anti-inflammatory effects of cannabinoids.
∆ CBDV: Another phytocannabinoid, cannabidivarin ( ), a direct analog of CBD derived from cannabigerovarin (CBGV), has shown a favorable pharmacokinetic profile and anticonvulsant effects. At micro-and nanomolar concentrations, it inhibits the reuptake of AEA and 2-AG.
: It is one of the important phytocannabinoids that is non-psychoactive. CBG potentially works as an antagonist of serotonin receptors. This data, along with other data, leads to the postulations that 5-HT2A receptor signaling is implicated in controlling neuronal excitability via GABAergic, glutamatergic, and monoaminergic neurotransmission. This acts as evidence of the possible anticonvulsant effects of CBG by direct modulation of activity at 5-HT2A receptors.
https://biomedican.com/cannabinoids-and-epilepsy-treatment/
https://wefunder.com/biomedican_inc?investor_panel=true